Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc.

Key Points

• Federated Hermes Inc. increased its stake in Keros Therapeutics by 882.3% in Q1, owning over 1.2 million shares worth approximately $12.5 million.
• Multiple analysts have lowered price targets for Keros Therapeutics, with Bank of America reducing its target from $32 to $18, indicating a shift in market sentiment.
• Keros Therapeutics reported earnings of $3.62 per share for the last quarter, significantly exceeding the consensus estimate of ($0.01), highlighting strong revenue performance.

Federated Hermes Inc. lifted its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 882.3% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,224,139 shares of the company's stock after purchasing an additional 1,099,519 shares during the quarter. Federated Hermes Inc. owned about 3.01% of Keros Therapeutics worth $12,474,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its holdings in shares of Keros Therapeutics by 5.4% during the 4th quarter. Vanguard Group Inc. now owns 1,957,109 shares of the company's stock valued at $30,981,000 after purchasing an additional 100,691 shares in the last quarter. Braidwell LP grew its stake in Keros Therapeutics by 167.9% in the 4th quarter. Braidwell LP now owns 1,894,439 shares of the company's stock valued at $29,989,000 after acquiring an additional 1,187,199 shares during the period. Darwin Global Management Ltd. grew its stake in Keros Therapeutics by 10.7% in the 4th quarter. Darwin Global Management Ltd. now owns 1,687,135 shares of the company's stock valued at $26,707,000 after acquiring an additional 163,403 shares during the period. Millennium Management LLC grew its stake in Keros Therapeutics by 53.3% in the 4th quarter. Millennium Management LLC now owns 878,159 shares of the company's stock valued at $13,901,000 after acquiring an additional 305,169 shares during the period. Finally, Geode Capital Management LLC grew its stake in Keros Therapeutics by 5.5% in the 4th quarter. Geode Capital Management LLC now owns 765,436 shares of the company's stock valued at $12,120,000 after acquiring an additional 39,815 shares during the period. 71.56% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. HC Wainwright lowered their target price on shares of Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Bank of America cut shares of Keros Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $32.00 to $18.00 in a research report on Tuesday, June 10th. Truist Financial lowered their price target on shares of Keros Therapeutics from $43.00 to $25.00 and set a "buy" rating on the stock in a research report on Wednesday, April 9th. Wedbush reissued a "neutral" rating and set a $15.00 price target on shares of Keros Therapeutics in a research report on Friday, May 30th. Finally, Scotiabank reduced their price objective on shares of Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday, May 12th. Seven investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $30.56.

Keros Therapeutics Stock Down 0.7%

Shares of Keros Therapeutics stock traded down $0.11 on Wednesday, hitting $14.29. 202,328 shares of the company's stock traded hands, compared to its average volume of 1,010,826. The stock has a market cap of $580.26 million, a P/E ratio of -79.20, a PEG ratio of 2.64 and a beta of 1.33. The firm's 50-day moving average is $14.06 and its 200 day moving average is $12.74. Keros Therapeutics, Inc. has a 52-week low of $9.12 and a 52-week high of $72.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $3.62 EPS for the quarter, beating the consensus estimate of ($0.01) by $3.63. The company had revenue of $211.25 million during the quarter, compared to analysts' expectations of $84.62 million. Keros Therapeutics had a return on equity of 0.75% and a net margin of 1.96%. During the same period in the prior year, the business posted ($1.21) EPS. Equities research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.